Fusion protein · Immune activation, directed at interferon alpha/beta receptor · developed by CytomX Therapeutics
CX-801 is a masked prodrug of interferon alpha-2b, with peptide masks linked by protease-cleavable linkers. The mask is cleaved by tumor-associated proteases in the tumor microenvironment, releasing active interferon alpha-2b that binds cell-surface interferon receptors and induces interferon-stimulated gene expression with immunomodulatory and antiproliferative effects. It is studied in adult solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06462794 | Phase 1 | Solid Tumor, Adult | Recruiting | CTMX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumor, Adult
See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTMX catalysts and pipeline →